Atherosclerosis
Volume 193, Issue 2 , Pages 366-372 , August 2007

A monocyte chemoattractant protein-1 gene polymorphism is associated with occult ischemia in a high-risk asymptomatic population

  • Min P. Kim

      Affiliations

    • Immunopathology Section, National Institute of Dental and Craniofacial Research, United States
    • ,
  • Larry M. Wahl

      Affiliations

    • Immunopathology Section, National Institute of Dental and Craniofacial Research, United States
    • ,
  • Lisa R. Yanek

      Affiliations

    • Division of Internal Medicine, The Johns Hopkins Sibling and Family Heart Study, The Johns Hopkins University School of Medicine, United States
    • ,
  • Diane M. Becker

      Affiliations

    • Division of Internal Medicine, The Johns Hopkins Sibling and Family Heart Study, The Johns Hopkins University School of Medicine, United States
    • ,
  • Lewis C. Becker

      Affiliations

    • Division of Cardiology, The Johns Hopkins Sibling and Family Heart Study, The Johns Hopkins University School of Medicine, United States
    • Corresponding Author InformationCorresponding author at: Halsted 500, Johns Hopkins Hospital, 600 N. Wolfe Street, Baltimore, MD 21287, United States. Tel.: +1 410 955 5997; fax: +1 410 955 0852.

Received 2 November 2005 ,Revised 27 April 2006 ,Accepted 25 June 2006.

References 

  1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  2. Takeya M, Yoshimura T, Leonard EJ, Takahashi K. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol. 1993;24:534–539
  3. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121–1127
  4. Yla-Herttuala S, Lipton BA, Rosenfeld ME, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA. 1991;88:5252–5256
  5. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275–281
  6. Gosling J, Slaymaker S, Gu L, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103:773–778
  7. Dawson TC, Kuziel WA, Osahar TA, Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 1999;143:205–211
  8. Yamashita T, Kawashima S, Ozaki M, et al. Propagermanium reduces atherosclerosis in apolipoprotein E knockout mice via inhibition of macrophage infiltration. Arterioscler Thromb Vasc Biol. 2002;22:969–974
  9. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999;259:344–348
  10. Tucci M, Barnes EV, Sobel ES, et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthrit Rheum. 2004;50:1842–1849
  11. Kruger B, Schroppel B, Ashkan R, et al. A monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol. 2002;13:2585–2589
  12. Aguilar F, Gonzalez-Escribano MF, Sanchez-Roman J, Nunez-Roldan A. MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens. 2001;58:335–338
  13. Szalai C, Duba J, Prohaszka Z, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 −2518G/G genotype in CAD patients. Atherosclerosis. 2001;158:233–239
  14. McDermott DH, Yang Q, Kathiresan S, et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation. 2005;112:1113–1120
  15. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002;347:1916–1923
  16. Simeoni E, Winkelmann BR, Hoffmann MM, et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J. 2004;25:1438–1446
  17. Alonso-Villaverde C, Coll B, Parra S, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation. 2004;110:2204–2209
  18. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report, National Institutes of Health. Obes Res. 1998;6(Suppl 2):51S–209S
  19. Frohlich ED, Grim C, LaBarthe DR, Maxwell MH, Perloff D, Weidman WH. Recommendations for human blood pressure determination by sphygmomanometers. Report of a special task force appointed by the Steering Committee, American Heart Association. Hypertension. 1988;11:209A–222A
  20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentrations of low-density lipoprotein (LDL) cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  21. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Circulation. 2002;106:3143–3421
  22. Blumenthal RS, Becker DM, Moy TF, Coresh J, Wilder LB, Becker LC. Exercise thallium tomography predicts future clinically manifest coronary heart disease in a high-risk asymptomatic population. Circulation. 1996;93:915–923
  23. Links JM, Becker LC, Rigo P, et al. Combined corrections for attenuation, depth-dependent blur, and motion in cardiac SPECT: a multicenter trial. J Nucl Cardiol. 2000;7:414–425
  24. Liang KY, Zeger SL. Regression analysis for correlated data. Annu Rev Public Health. 1993;14:43–68
  25. Greenland P, Smith SC, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people. Role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104:1863–1867
  26. Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis. 1986;39:809–821
  27. Blumenthal RS, Becker DM, Yanek LR, et al. Detecting occult coronary disease in a high-risk asymptomatic population. Circulation. 2003;107:702–707
  28. Cho ML, Kim JY, Ko HJ, et al. The MCP-1 promoter −2518 polymorphism in Behcet's disease: correlation between allele types, MCP-1 production and clinical symptoms among Korean patients. Autoimmunity. 2004;37:77–80
  29. Ueda A, Okuda K, Ohno S, et al. NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol. 1994;153:2052–2063
  30. Valente AJ, Xie JF, Abramova MA, Wenzel UO, Abboud HE, Graves DT. A complex element regulates IFN-gamma-stimulated monocyte chemoattractant protein-1 gene transcription. J Immunol. 1998;161:3719–3728
  31. Tabara Y, Kohara K, Yamamoto Y, et al. Polymorphism of the monocyte chemoattractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not with carotid intima media thickness. Hypertens Res. 2003;26:677–683
  32. Hwang SY, Cho ML, Park B, et al. Allelic frequency of the MCP-1 promoter −2518 polymorphism in the Korean population and in Korean patients with rheumatoid arthritis, systemic lupus erythematosus and adult-onset Still's disease. Eur J Immunogenet. 2002;29:413–416
  33. Jibiki T, Terai M, Shima M, et al. Monocyte chemoattractant protein 1 gene regulatory region polymorphism and serum levels of monocyte chemoattractant protein 1 in Japanese patients with Kawasaki disease. Arthrit Rheum. 2001;44:2211–2212
  34. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391–397
  35. Tracy RP, Psaty BM, Macy E, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167–2176
  36. Kiechl S, Werner P, Egger G, et al. Active and passive smoking, chronic infections, and the risk of carotid atherosclerosis: prospective results from the Bruneck Study. Stroke. 2002;33:2170–2176
  37. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531–2534
  38. Zhou P, Thomassen MJ, Pettay J, Deodhar SD, Barna BP. Human monocytes produce monocyte chemoattractant protein 1 (MCP-1) in response to a synthetic peptide derived from C-reactive protein. Clin Immunol Immunopathol. 1995;74:84–88
  39. Sekine O, Nishio Y, Egawa K, Nakamura T, Maegawa H, Kashiwagi A. Insulin activates CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. J Biol Chem. 2002;277:36631–36639
  40. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA. 2003;100:7265–7270
  41. Simeoni E, Hoffmann MM, Winkelmann BR, et al.. Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and type 2 diabetes mellitus. Diabetologia 2004 [Epub ahead of print].

PII: S0021-9150(06)00395-9

doi: 10.1016/j.atherosclerosis.2006.06.029

Atherosclerosis
Volume 193, Issue 2 , Pages 366-372 , August 2007

Article Tools

* Image Usage & Resolution